PHAXIAM Therapeutics SA (PHXM) Stock Income Statement
NASDAQ:PHXM - Nasdaq - US29604W2070 - ADR - Currency: USD
| 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|
| Revenue | 6.65M | 4.18M | 3.72M | |||
| Operating Expenses | 33.80M | 60.70M | 72.55M | |||
| Research and Development | 15.91M | 40.22M | 53.35M | |||
| Selling, General, and Administrative Expenses | 13.26M | 15.10M | 14.52M | |||
| Operating Income | -27.15M | -56.52M | -68.83M | |||
| Interest Income/Expense | 4.13M | 3.28M | -1.27M | |||
| Other Income/Expense | -1.04M | -564.00K | -3.19M | |||
| Non Recurring Items | 24.35M | N/A | N/A | |||
| Income Before Taxes | 293.00K | -53.80M | -73.30M | |||
| Income Tax | 521.00K | 2.00K | 3.00K | |||
| Net Income | -228.00K | -53.80M | -73.30M | |||
| EBITDA | -22.53M | -51.14M | -63.84M | |||
| Per Share Data | ||||||
| EPS Diluted Total Ops | -0.04 | -12.28 | -21.55 | |||
| Statistics | ||||||
| Profit Margin | -3.43% | -1287.01% | -1971.49% | |||
| Operating Profit Margin | -408.35% | -1352.03% | -1851.32% | |||
All data in EUR